Non-rhabdomyosarcoma soft-tissue sarcoma.
Sarah A MilgromLynn MillionHenry MandevilleAkmal SafwatRalph P ErmoianStephanie A TerezakisPublished in: Pediatric blood & cancer (2021)
Non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) comprise 4% of childhood cancers and consist of numerous histologic subtypes. Prognostic factors associated with poor outcome include high histologic grade, large tumor size, presence of metastases, and unresectability. Complete surgical resection is critical for the best oncologic outcomes and is prioritized in treatment algorithms. The use of radiation therapy (RT) and chemotherapy is based upon factors such as resectability, histologic grade, tumor size, and stage. North American and European trials are defining a risk-based approach to NRSTS to limit treatment-related toxicity and to maximize therapeutic efficacy. In this paper, we summarize the current roles of surgery, RT, and chemotherapy in NRSTS and describe ongoing research that is advancing the care of NRSTS patients.
Keyphrases
- radiation therapy
- end stage renal disease
- healthcare
- locally advanced
- soft tissue
- machine learning
- ejection fraction
- newly diagnosed
- palliative care
- prognostic factors
- squamous cell carcinoma
- chronic kidney disease
- oxidative stress
- prostate cancer
- type diabetes
- peritoneal dialysis
- deep learning
- acute coronary syndrome
- coronary artery disease
- coronary artery bypass
- combination therapy
- replacement therapy
- glycemic control
- chronic pain
- pain management
- patient reported outcomes
- childhood cancer